Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Intel reaches its October 22 earnings print having given back $24 from the late-September high, with shorts at a post-squeeze record, peers falling hard across the board, and a CEO buy from August still the most bullish insider signal on the table.
The weekly decline of 8.6% dropped the stock to $102.81, its lowest close since the big AI-driven rally took hold. What is different this week is that the selloff is no longer stock-specific. AMD fell 6.8% over the same five days. MXL dropped 18.9%. LRCX lost 9.8%. gave back 12%. The whole semiconductor complex has pulled back sharply, which removes the "Intel underperforming peers" read that shaped the prior two notes and replaces it with a sector-level question heading into earnings season.
Short positioning reached a new high for this cycle, but the lending market is completely relaxed. Short interest has climbed to 3.51% of free float, up 2.7% on the week and 22% over the past month. That is the highest reading since at least early July, with the trend accelerating through September and into October. Cost to borrow has doubled over the week to 0.52%, the sharpest short-dated move in the 30-day history, though the absolute level remains low. Availability is effectively unlimited: over 5.2 billion shares remain available to borrow, and the borrow market shows no sign of tightness. There is no squeeze pressure here. Shorts are adding at scale because the stock has moved, not because they are being forced out of anything. Options traders, meanwhile, are entirely calm. The put/call ratio is running at 0.86, almost exactly in line with its 20-day average of 0.86 and a z-score near zero. There is no unusual hedging demand heading into the print.
The Street is cautiously constructive, but barely. The consensus is Hold, with 31 analysts on the name and a mean target of $118.48, roughly 15% above Tuesday's close. Mizuho raised its target from $92 to $114 in early October, keeping a Neutral rating. That is meaningful context: the most recent target move was an upgrade in price terms, not a cut, and came after the stock had already pulled back from $127. Tigress Financial sits at $145 with a Buy. Piper Sandler initiated in September at Neutral with a $110 target, essentially in line with where the stock now trades. The EPS momentum scores are strong, ranking in the 87th percentile over 90 days and the 65th percentile over 30 days, which suggests estimate revisions have been running in the right direction. The EV/EBIT multiple, however, ranks in just the 9th percentile, a clear warning that the stock carries a heavy valuation burden even after the recent pullback. The bull case rests on Q2's 25% revenue growth and 59% jump in Data Center and AI revenue as evidence that the turnaround is real. The bear case questions how much foundry external revenue Intel can actually secure, modelling less than $2 billion even with advanced packaging included.
The most concrete bullish data point in the snapshot remains CEO Lip-Bu Tan's $10 million open-market purchase at $95 per share, filed on August 11. That trade, made without a 10b5-1 plan, was a discretionary bet at a price 8% below Tuesday's close. It is the kind of insider signal that holds weight. Net insider activity over the 90 days to that date was a positive 84,239 shares worth roughly $7.5 million. Nothing has been filed since, so the August buy is still the last word from inside the house going into earnings.
Intel has fallen more than 8% on the day after each of its last three earnings reports, and further over the following week. The October 22 print lands eight days from now. What to watch is whether Q3 revenue holds anywhere near Q2's $16.1 billion pace, and whether the foundry segment can show external customer traction beyond the internal transfer pricing that currently drives most of that line's reported growth.
See the live data behind this article on ORTEX.
Open INTC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.